Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy
Prostate Cancer, Osteoporosis, Fractures
About this trial
This is an interventional prevention trial for Prostate Cancer focused on measuring Prostate cancer, Bone Loss, Osteoporosis, Fractures, Androgen Deprivation Therapy
Eligibility Criteria
Inclusion Criteria: To be eligible for participation in this study, subjects must meet all of the following criteria (minor deviations may be discussed with the medical monitor for possible inclusions): Give voluntary, signed informed consent in accordance with institutional policies Be male, aged ≥ 50 years Have histologically documented prostate cancer. Subjects with metastatic prostate cancer may still be considered for the study as long as they are not disqualified by other inclusion/exclusion criteria and there is a reasonable expectation that their medical condition will not interfere with the objectives of the study and that adequate follow-up and compliance with the study protocol can be achieved for the full 24-month duration of the study. Have been on: ADT treatment (either luteinizing hormone-releasing agonist [LHRHa] or orchiectomy) for at least 6 months; Or Intermittent LHRHa for at least the preceding 12 months is acceptable, but subjects must be maintained on uninterrupted treatment for the duration of this study once they are randomized into the study. Be aged ≥ 70 years or have BMD of lumbar spine or femoral neck at or below the specified thresholds for study entry: Hologic BMD (g/cm2): L1-L4 - 0.926; Femoral neck - 0.717 Lunar BMD (g/cm2): L1-L4 - 1.050; Femoral neck - 0.840 Serum prostate-specific antigen (PSA) ≤ 4 ng/mL Have a Zubrod performance status ≤ 1 Subject weight < 300 lbs (weight limitation of DEXA equipment) Agree to complete a daily diary of medication intake and to provide tablet containers for accurate counts Agree to use an effective method of contraception, if the partner is of childbearing age, while on study Have adequate bone marrow, liver and renal function: White blood cell (WBC) count ≥ 3,000/mm3; Platelet count ≥ 100,000/mm3; Bilirubin ≤ 1.5 mg/dL; AST and ALT < 2x upper limit of normal; Serum creatinine ≤ 2.0 mg%. Exclusion Criteria: Subjects with any of the following will not be eligible for enrollment: Taking bisphosphonates, selective estrogen receptor modulators (SERMs), parathyroid hormone (PTH), Forteo® (teriparatide), calcitonin, or oral glucocorticoids within 45 days of randomization Have any disease or condition that would preclude an accurate evaluation of radiographs of the thoracic and lumbar spine (at least eight evaluable vertebrae in the range T4 to L4) [for example, severe scoliosis, or sequelae of orthopedic procedures or other surgery] Have > 4 vertebral fragility fractures Have any history of other carcinomas within the last 5 years (except nonmelanoma cutaneous malignancies and superficial bladder cancer with no evidence of recurrence which will not be excluded). NOTE: Patients with cancers other than nonmelanoma cutaneous malignancies and superficial bladder cancer with no evidence of tumor recurrence for at least 5 years after definitive treatment will not be excluded from this study. Have Paget's disease of bone Have active systemic viral, bacterial or fungal infections requiring treatment Have, in the judgment of the investigator, a clinically significant concurrent illness or psychological, familial, sociological, geographical or other concomitant condition that would not permit adequate follow-up and compliance with the study protocol for the full 24-month duration of the study Received treatment with other investigational agents within 30 days prior to randomization Taking finasteride (e.g., Proscar®), dutasteride (e.g., Avodart®), Danocrine® (danazol) or testosterone-like supplements, such as dehydroepiandrosterone (DHEA) [subject is eligible if he stops these agents for a total washout of 45 days prior to randomization and agrees not to use these agents for the duration of the study] Taking herbal medicine or dietary supplements for prostate health, such as PC SPES and saw palmetto (also known as Serenoa repens) [subject is eligible if he stops these agents for a total washout of 45 days prior to randomization and agrees not to use these agents for the duration of the study]. Lycopene and selenium are not prohibited and no washout is required. Have a history of thromboembolic disease including deep vein thrombosis or pulmonary embolus Have a history of chronic hepatitis or cirrhosis Have received prior treatment with toremifene
Sites / Locations
- Urology Centers of Alabama
- Coastal Clinical Research
- Arkansas Urology
- Advanced Urology Medical Center Clinical Trials
- Urological Sciences Research Foudation
- Urological Associates of Central CA
- Center of Urologic Research
- South Orange County Medical Research Center
- Palo Alto VA
- San Bernadino Urological Associates
- Urological Physicians of San Diego
- Veterans Medical Research Foundation
- Pacific Clinical Research
- West Coast Clinical Research
- Western Clinical Research, Inc.
- Urology Associates
- Western Urological Research
- Urologic Center
- Urological Associates of Bridgeport
- Connecticut Clinical Research
- Walter Reed Army Medical Center
- South Florida Medical Research
- Urology Consultants Inc.
- Atlantic Urological Associates
- Urosearch
- Lakeland Regional Medical Center
- Advance Research Institute
- Central Florida Urology Group/ UroSearch
- Florida Foundation for Healthcare Research
- Winter Park Urology Associates
- Panama City Urology
- Pinellas Urology
- Southeastern Research Group
- Tampa Bay Urology
- UroSearch
- Cleveland Clinic-Florida
- Midtown Urology
- Georgia Urology
- St. Joseph Research Institute
- Augusta VAMC
- Southeastern Medical Research Institute
- Urology Enterprises
- Harbin Clinic Department of Urology Research
- North Fulton Urology
- St. Joseph's, Candler Health System
- North Idaho Urology
- Prairie Medical Associates
- Medical and Surgical Specialists
- Special Care Research
- Urology of Indiana, LLC
- MMPC Urology
- Metropolitan Urology
- Heartland Research Associates, LLC
- LSUHSC/Stanley Scott Cancer Center
- Regional Urology LLC
- Anne Arundel Urology P.A.
- Maryland Prostate Center: University of Maryland Medical Center
- Urology Center, PA
- Mid Atlantic Clinical Research
- The Fallon Clinic
- Wayne Glazier
- University of Michigan Comprehensive Cancer Center
- Beaumont Medical
- Mayo Clinic Urology Department
- Park Nicollet Urology
- Kansas City Urology, PC
- PPS Clinical Research
- Urologic Research Center
- Sheldon Freeman
- Urologic Surgeons, Ltd.
- Coastal Urology Associates
- Hamilton Urology PA
- Lawrenceville Urology Associates
- Assoc. Urologic Specialists
- Urology Healthcare Associates
- Urology Group of New Mexico
- Urology Inst. Of New York
- William Oberheim
- Metropolitan Urologic Services, PC
- Urological Surgeons of Long Island
- University Urology Associates
- Mount Sinai School of Medicine
- CNY Urology
- Staten Island Urological Research , PC
- Associated Urologists of CNY
- Center for Urologic Research WNY, LLC
- Asheboro Urology
- University of North Carolina
- The Urology Center
- Wake Urology
- Piedmont Medical Research Associates
- Odyssey Research
- Summa Health Care
- The Urology Group
- Cleveland Clinic Lerner College of Medicine
- Colombus Urology Research
- Urology of Northern Ohio
- Southwest Urology
- Oklahoma University Medical Center
- Urologic Specialists of Oklahoma, Inc.
- The Corvallis Clinic
- Oregon Urology Specialists
- Urologic Associates of Allentown
- Urologic Surgery
- Urological Associates of Lancaster, Ltd.
- The Urology Institute
- University of Pennsylvania
- Ginsberg and Harkaway Urology
- University of Pittsburgh
- State College Urologic Association
- University Urological Research Institute
- Radiant Research
- Carolina Urologic Research Center
- Volunteer Research Group
- Southeast Urology Network
- Ace Research Specialists
- Center for Urological Treatment
- Urology Associates
- Vanderbilt Medical Center
- Professional Quality Research
- Breco Research
- Urology Consultants, PA
- Urology San Antonio Research, PA
- Scott and White Clinical Hospital
- Salt Lake City Research
- Adult and Pediatric Urologists of Northern VA
- Devine Tidewater Urology
- Med Atlantic, Inc (Virginia Urology)
- McGuire VA Medical Center
- Seattle VAMC
- Deaconess Medical Center
- Madigan Army Medical Center
- University of Wisconsin Medical School: Clinical Trials
- St. Michael's Hospital
- Froedtert Memorial Lutheran Hospital Department of Urology
- Wyoming Research Foundation
- American British Cowdray Hospital
- Centro Medico Dalinde
- Hospital General de Mexico
- Hospital Regional "Gabriel Mancera", IMSS
- Centro Medico Naval
- Hospital General de Zona No. 1-A
- Clinica Londres
- Hospital Central Militar, SDN
- Hospital Medica Sur
- Hospital de Oncologia CMN Siglo XXI, IMSS
- Hospital General de Zona No. 26, Mexico D.F.
- Hospital General Region 1 de Octubre, ISSSTE
- Hospital Civil Viejo "Fray Antonio Alcalde"
- Centro Medico de Occidente-IMSS
- Hospital Regional Dr Valentin Gomez Farias, ISSSTE
- Hospital Regional de Especialidades
- Hospital Universitario
- Hospital Ignacio Morones Prieto
- Hospital General de Zona con UMF No. 2 San Luis Potosi